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Importance of a highly controlled volume balance on patient hemody-
namic during plasma exchange: Advantages of a computer assisted
reinfusion system. H. Favre and D. Claeysen, Division de Néphrologie HCU
Genève, Geneva, Switzerland. Continuous renal replacement therapies
used in the treatment of acute renal failure patients are considered to
preserve hemodynaniic stability even in severely compromised patients. In
our hands, computer assisted continuous venovcnous hemofiltration
(caCVVH) provides a better stability of the hemodynamic parameters
than classical manual CVVH (niCVVH), where fluid substitution rate is
first estimated and then adjusted every hour to match the ultrafiltration
rate. To assess the potential benefit of a continuously adjusted fluid
replacement, 19 patients receiving plasma exchange using a PF2000 filter(Gambro) indicated for neurological diseases (polyradiculonevritis or
myasthenis gavis) were studied when treated: (a) with manual method
using an AKI0 blood module (Gambro), and (b) with a computer assisted
technique: same blood circuit as for manual method; reinjection rate of
the substitution fluid calculated by a computer which records every 30
seconds the ultrafiltration rate (weight) and drives a pump delivering an
equal amount of restitution fluid (FJ-Tech). Three liters of plasma
ultrafiltrate were substituted by a 5% albumin-saline solution providing, in
the absence of changes in plasma osmolality and chemical composition, a
unique opportunity to evaluate the volume-dependent hemodynamic
component. The manual method requires 3 hours if one has to avoid
clinically relevant errors in the fluid balance during the procedure; the
same operation is feasible in 45 minutes when using caCVVH. Compar-
ison of hemodynamic stability as assessed by 4 to 7 blood pressure (BP)
measurements recorded during 19 mCVVH versus 19 caCVVH treat-
ments demonstrates a perfect hemodynamic stability when using
caCVVH-intratreatment BP variations: caCVVH versus mCVVH; F value
89.58; P < 0.0001. In conclusion, permanent adjustment of the fluid
balance is needed to maintain the hemodynamic stability in patients
treated by plasma exchange or hemo/hemodiafiltration.
Prognosis of living-related-donor transplantation in IgA nephropathy.
D. Tsinalis, Mi. Mihatsch, G. Thiet, HA. Bock, and C. Zehnder, University
of Wurzburg, Germany; Kantonsspital Basel, Basel; and Kantonsspital
.4arau, Aarau, Switzerland. Mesangial IgA deposits recur in many patients
receiving a renal allograft for end-stage renal disease due to IgA nephrop-
athy. The aim of this study was to determine if there are differences in
prognosis between living-related donor versus cadaver kidney recipients
with IgA nephropathy. We studied 21 kidney transplant recipients with
biopsy-proven IgA nephropathy as their primary disease who were trans-
planted in Basel between 1981 and 1991. Nine of these patients had
received a graft from a living-related kidney donor, 12 from a cadaver
kidney. Median follow-up was 3.4 years (2 to 10). The two groups were not
different with respect to gender distribution, integral cyclosporine A level
over time, integral azathioprine and prednisone dose and time of follow-
up. Living kidney recipients were younger than cadaver recipients (30 3
vs. 43 3 years, P < 0.01). The overall recurrence rate of IgA
nephropathy, defined as mesangial IgA deposits associated with mesangial
proliferation was 33% (7 of 21). The recurrence rate in the living related
kidney recipients was higher [44% (4 of 9) vs. 25% (3 of 12); P = NSI.
Consistent with this higher recurrence rate, living kidney recipients
accounted for 8 of 15 biopsy-proven IgA recurrences (53%) in Basel
between 1981 and 1994, whereas the proportion of living donor kidney
recipients transplanted during this time was much smaller (66 of 525
transplants = 13%; P < 0.001). The living-related group had, however, a
lower incidence of rejection episodes (number of methylprednisolone
pulse triplets: 3.2 0.7 episodes vs. 4.2 0.5; P < 0.05) and a better graft
function at the end of follow-up (Cockroft-Gault estimate of creatinine
clearance: 62 8 vs. 36 7 mI/mm; P < 0.01). During follow-up, 6
kidneys were lost due to death of the recipient, three by rejection and only
one from recurrence of IgA nephropathy (a cadaver kidney recipient). We
conclude that the higher risk of recurrent IgA nephropathy in living-
related donor transplantation may be accepted for the benefit of less
rejection episodes, which appear to be more relevant for graft function
than the recurrence of original disease.
Relevance of glomerulonephritis recurrence for transplant out-
come—An analysis of 208 grafts from 1980—1994. E. UlImer, Mi. Mi-
hatsch, G. Thiel, and HA. Bock, Abteilung für Nephrologie und Institut für
Pathologic, Kantonsspital Basel, Basel, Switzerland. The present study was
designed to evaluate the incidence and prognosis of glomerulonephritis
recurrence after kidney transplantation. The charts of all 183 patients
transplanted in Basel between 1.1.80 and 30.6.94 (N = 208 transplanta-
tiOns) with a primary diagnosis of glomerulonephritis were reviewed. In 91
grafts, the GN type was either unknown or the biopsy was equivocal; 25
additional recipients belonged to smaller GN groups. The remaining
92 patients had a positive GN diagnosis in their native kidney biopsy
for either membranoproliferative GN type I (MPGN), IgA-Nephritis
(IgANP), primary (immunological) focal sclerosis (FSGS) or epimembra-
nous GN (EpiMGN). They were evaluated with respect to histological
recurrence (HistoRec), clinical recurrence (ClinRec: the first occurrence
of proteinuria or glomerular microhematuria after transplantation) and
prognosis. Data are summarized below:
N Cadaver/Living donor
HistoRec
Cadaver Living donor
MPGN
IgANP
FSGS
EpiMGN
28 25/3
28 15/13
23 21/2
13 11/2
8/25 (32%)
3/15 (20%)
4/21 (19%)
4/11 (36%)
0/3 (0%)
5/13 (39%)
0/2 (0%)
0/2(0%)
Days to ClinRec
SEM)
5 year
graft
survival
Graft loss
from GN
Time to
loss ty, yr.)
MPGN
IgANP
FSGS
EpiMGN
80 31
498 133
41 19
63%
74%
64%
51%
5(18%)
1(4%)
2 (9%)
2(15%)
3.4
6.4
3.1
1.9
P < 0.05 IgANP vs. MPGN/EpiMGN; h Recurrence was immediate in
3 grafts; one patient developed EpiMGN after 2½ years.
© 1996 by the International Society of Nephrology
Recurrence rates did not differ significantly between cadaver and living
donor kidneys and among the four GN types. MPGN, EpiM and FSGS
recurred much faster than IgA nephropathy. Recurrences were clinically
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apparent within days for FSGS, within 3 months for Ep1MGN and within
8 months for MPGN, whereas many recurrences appeared beyond the first
year in IgANP. No living donor graft in the four study groups was lost from
recurrence. The 5-year graft survival for non-GN patients transplanted
during the same period was 67%, similar to the one of GN patients.
Conclusions Glomerulonephritis recurs in 20 to 30% of grafts. While
recurrence often leads to graft loss in FSGS, MPGN and EpiMGN, most
grafts continue to function for at least 3 years even with recurrence. Graft
loss from recurrent IgANP is unusual. Unless early graft loss by recurrence
is individually documented, there is no reason to exclude GN patients
from kidney transplantation in general and from living related donor
transplantation in particular.
Aathioprine and 6-mercaptopurine levels: Potential use for therapeu-
tic monitoring. HR. Räz, H.A. Bock, C. Peterson, and C. Thiel, Abteilung
für Nephrologie, Kantonsspital, Basel, Switzerland; and Department of
Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden. It has only
recently become possible to specifically measure the plasma levels of
azathioprine (Aza) and its active metabolite 6-mercaptopurine (6MP). We
tried to find out whether an Aza- and 6MP-level 2 hoors post-oral dose
would reasonably represent the area under the curve 0—6 hr (AUC(O6 hr))
for Aza/6MP and therefore could be used for therapeutic monitoring in
kidney transplant patients. Methods: (1) Aza/6MP-AUC(O_b hr) including
a 2 hour post-dose level was measured in 11 kidney transplant patients
who took Aza as part of their regular medication. (2) 2 hour post-dose
levels of Aza and 6MP were measured in 2 separate groups of kidney
transplant recipients on regular Aza medication: (a) 12 "Aza-sensitive"
patients taking less than 0.8 mg Aza/kg body weight because of previous
leukopenia, and (b) 15 control patients taking more than 1.5 mg Aza/kg
body weight. Results: (1) 2 hours post-dose Aza and 6MP-levels correlated
well with Aza- and 6MP AUC(O_(, br) (Aza: r = 0.81, P < 0.005; 6MP: r =
0.86, P < 0.005). (2) The "low" and "high" dose Aza patients were similar
with respect to body weight and serum creatinine. Mean values (± SEM)
for Aza/fiMP doses and levels are given below:
Aza sensitive Control P'
Aza dose/kg body wt, mg/kg 0.6 0.1 1.9 0.1 <0.01
Aza level at 2 hours nmol/liter 16.6 5.7 59.8 26.4 NS
6MP level at 2 hours nmol/liter 20.1 5.9 27.4 5.8 NS
Aza level per Aza dos&'
6MP level per Aza doset
28.2 8.3
36.7 9.0
30.8 13.1
14.8 3.3
NS
<0.05
a unpaired t-test; nmol/liter per mg/kg
Despite a 3- to 4-fold difference in Aza dose and 2 hour Aza levels, 2
hour-6MP levels in the two groups were very similar, pointing to either an
increased Aza to 6MP-conversion or a decreased 6MP clearance in the
"Aza-sensitive" patients. Neither Aza nor 6MP levels were predictable
from Aza dose. Conclusions: (1) 2 hours post-oral dose levels of Aza and
6MP correlate sufficiently well with AUC to be used for therapeutic
monitoring. (2) Patients who develop leukopenia under Aza therapy
appear to have relatively higher 6MP levels than controls. (3) Monitoring
2 hours post-dose Aza and 6MP levels could help to avoid underdosage or
leukopenia in Aza-treated kidney transplant recipients.
Renal proximal sodium handling and response to a high sodium diet in
patients with postural hypotension. .4. Pechère-Bertschi, J. Biollaz, L.
Decosterd, C. Fahti, C. Centeno, and M. Burnier, University Hospital,
Lausanne, Switzerland. An increase in renal sodium excretion in recum-
bant position has been implicated in the pathogenesis of idiopathic
postural hypotension (IPH). In this study, the day- and night-time
variations in blood pressure (BP) and segmental sodium handling were
measured on a free sodium diet in 21 patients with 1PM and 18 controls
(C). In addition, 10 patients and 10 controls were studied after one week
of high sodium diet (+6 g NACI/day). IPl-I was defined by the reporting of
symptoms upon assuming the upright position and by a positive orthostatic
test. A 24 hour BP recording was obtained by intermittent (30 mm
intervals) ambulatory BP monitoring. Simultaneously, urines were col-
lected from 8:00 am. to 10:00 p.m. and from 10:00 p.m. to 8:00 am. to
measure day- and night-time electrolytes excretion. Segmental sodium
reabsorption was assessed by the determination of endogenous lithium in
blood and urine, by urinary sodium excretion and subsequent calculation
of the fractional excretion of sodium (FENa) and lithium (FELl). A fall in
blood pressure during the night was observed both in C (114.2/80.5
0.4/0.5 to 99.9/67.8 1.3/1.3, mean suM) and IPH (121/82.2 0.8/0.6 to
107.2/71.2 1.6/1.38). Both day- and night-time systolic and diastolic BP
were significantly higher in IPH than in C. The FEL/FENU ratio, indicating
the contribution of the proximal tubule segment to the overall sodium
excretion, increased significantly from day to night in IPH (from 24 2 to
36.3 3.7, P < 0.01), whereas no difference was found in C (from 29.5
2 to 32.2 3.3). On a high salt intake, BP increased in C (from
114.2/80.5 0.4/0.5 to 116.4/82.8 ii 0.5/0.5, P < 0.01) at day-time period,
and from 99.9/67.8 1.3/1.3 to 106.2/74 1.7/1.6 during the night, P <
0.01), but there was no change in IPH. After sodium loading, the
FELi/FENa ratio is again lower during the day than during night time in
IPH (22.2 3.2 vs. 40.3 10.2, respectively, P = 0.08), but there is no
difference throughout the day in C (20.4 2.2 in day-time vs. 21.6 1.7
during night-time, P = 0.65). These results suggest that on a normal salt
intake, the proximal sodium reabsorption tends to be higher in IPH during
day-time, possibly due to repeated falls in BP. After sodium loading, the
relative sodium escape from the proximal tubule becomes comparable in
IPH and C during the day. However, the FELi/FENa ratio remains high
during the night in IPH but decreases in C. This suggests that the proximal
tubular segment of patients with postural hypotension retains less sodium
upon loading than normal subjects during the night.
Rescue therapy with tacrolimus (FK506) in recurrent/resistant rejec-
tion under ciclosporine A. HA. Bock, I. Binet, and C. Thiel, Abteilung
Nephrologie, Kantonsspital Basel, Basel, Switzerland. We report the first
experience with tacrolimus-based immunosuppression in Swiss kidney
transplant recipients. Between May 1993 and July 1995, 15 rejecting renal
transplant recipients from our center were switched from a cyclosporine A
based immunosuppression to tacrolimus in an attempt to rescue the graft.
Vascular rejection was documented in all 15 patients who were otherwise
considered unsuitable for further intense immunosuppression. Specific
indications included: (A) recurrent acute vascular rejection (2 acute
rejections with primary response to MP pulse or antibody therapy, hut
relapse despite high-dose triple therapy, N = 8); (B) antibody-resistant
acute rejection (n = 2); and (C) chronic rejection with a biopsy-proven
acute component (usually transplant glomerulitis, N = 5). At the time of
switching (median 110 days after transplantation for Groups A and B, 3.6
years for Group C), these patients had received anti-lymphocyte antibody
therapy for a median of 14 days (range 0 to 28). The group included 10
first transplants (2 were living donor kidney recipients). The initial
tacrolimus dose was 0.2—0.3 mg/kg/day in two doses; it was later adjusted
for 12-hour target trough levels of 8 to 15 ng/ml. Side effects were mild and
essentially consisted of tremor in 2/3 of cases and transient diarrhea in 3
patients. They usually occurred early after switching, when tacrolimus
levels were often >20 ng/ml; a transient increase in creatinine was
frequently seen at the same time. Outcome data are summarized below:
Type of Functioning
Median (range) or individual data
(functioning grafts only)
Follow-up (r at 5Cr at
rejection N at follow-up time, days switch follow-up
8 6Recurrent
(Grou A) 196 369 218
Antibody- 2 1 (158—774) (138—800) (126—518)
resistant
(Group B)
Chronic 5 3 55, 142, 135, 238, 146, 484,
(Group C) 322 243 296
In conclusion, switching to tacrolimus has an approximate 70% success
rate in acute recurrent or antibody resistant rejection. Patients responding
to this therapy not only maintain, hut usually improve their renal function.
So far, there seems to be no benefit in chronic types of rejection. A switch
to tacrolimus should be considered early in recurrent or antibody resistant
rejection.
Lnterleukin-2 receptor (IL-2R) up-regulation after T cell costimulation
with the PrP-specific monoclonal antibody (mAb) 3F4. G. Halabi and R.
Loertscher, Transplant Immunology Laboratory, Department of Medicine,
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Royal Victoria Hospital, and McGill University, Montreal, QC Canada. Thc
cellular prion protein (PrPC) is anchored to the membrane of lymphocytes
through a glycosyl phosphatidyl inositol (GPI) moiety. PrPC, as other
GPI-linked proteins (for example CD55, CD59), coprecipitates with a
protein kinase activity. It was the purpose of this study to examine the
possibility to provide to naive T cells a stimulatory signal through PrP".
Purified T cells were prepared by negative selection with mAb's to
HLA-DR, CD1 1 b, CD16 and CD57. Purity of T cells was in excess of 95%,
and macrophage contamination was less than 1% as judged by CD14
staining. Titration studies with mAb's OKT3 (CD3) and OKT 11 (CD2)
established that suboptimal stimulation required 1—2 g/ml and 2 gIml of
OKT3 and OKT1 1, respectively. In 9 separate experiments addition of the
PrPcspecific mAb 3F4 at 1 jzg/ml enhanced the proliferative response by
an average of 24 18%, 55 24% and 69 46% when OKT3 was used
at 1, 2 and 4 sg/ml, respectively. Non-binding mouse IgG at 1 jsg/ml was
used for control purposes. In two separate experiments T cells were
analyzed by flow cytometry for the expression of IL-2R (CD25). After 3
days of suboptimal stimulation, 11.9—28.9% of T cells expressed CD25.
This proportion increased to 21.1—38.4% after costimulation with mAb
3F4. Median immunofluorescence as a relative measure of CD25 copy
number increased correspondingly to 14.3—22.1 from 8.4—13.3 arbitrary
units. A preliminary determination of IL-2 production by CTLL-2 bioas-
say revealed a minimal excess of this cytokine after 3F4 costimulation. We
conclude that PrP' may provide a costimulatory signal to suboptimally
stimulated T cells, and that this signal induces an up-regulation of IL-2R
a chain expression.
Is younger age a risk factor for renal damage in pyelonephritis? N.
Benador, D. Benador, D. Slosmann, and E. Girardin, Département de
Pédiatrie, and Division de Médecine Nucléaire, Genève, Switzerland. Pyelo-
nephritis in children may lead to renal damage and previous studies
suggest that renal involvement is the highest during the first year of life
and lower after the age of 5 years. In this prospective study, the relative
risk to develop renal involvement in relation to age was assessed with
dimercaptosuccinic acid scintigraphy (DMSA scan), a method more
sensitive than ultrasonography or intravenous urography to diagnose renal
lesions. One hundred eighty-three patients I week to 16 years of age
(median 7.1 months), with a positive urine culture and a DMSA scan
performed within the first 5 days of the hospitalization were included in
the study. The DMSA scan was repeated in 34 children after a mean
follow-up of 10.2 months. Children were divided into 3 groups: <1 year,
1—5 years and >5 years.
<1 year 1—5 years >5 yearsN % N % N %
Initial work up renal lesions 66/1 14 (58) 21/32 (66) 32/37 (86)
Follow up scars 7/18 (39) 3/5 (60) 9/11 (82)
The comparison of the 3 groups of age showed that the incidence of renal
lesions at initial work up increased with age (P = 0.006). For the children
with a follow-up DMSA scan, the incidence of renal scars was not
significantly different between the 3 groups (P = 0.07). Among patients
investigated by a voiding cystourethrogram, vesicoureteric reflux was
absent in 56 of 94 children with renal lesions at the initial work up and in
4 of 19 children with scars. In conclusion, in this study we did not confirm
the higher incidence of renal damage in young children. On the contrary,
our results show in older patients a tendency to develop more lesions.
Therefore, we suggest that all children with suspected pyelonephritis,
regardless of the age, require effective diagnostic and therapeutic mea-
sures as usually performed in infants.
Capillary filtration coefficient (CFC) and refilling rate (RR) as influ-
enced by ultrafiltration and/or sodium profiling during hemodialysis. A.
Knoflach, II. Kubista, and U Binswanger, Universitatsspital Zurich, Zurich,
Switzerland. Five chronic HD patients were studied 4 times during the first
hour of: regular treatment; Na dialysate concentration 150 mmol/liter;
ultrafiltration 50% of total fluid removal during whole treatment; and
combined high sodium dialysate plus high initial ultrafiltration using an
Althin apparatus. Relative blood volume changes were monitored con-
tinously by means of ultrasound-based density measurements (Dr. J.
Stabinger, Graz, Austria). Results were as follows (mean SD, normalized
to lean-body-mass 50, LBM).
Treatment
CFC ml/
mm mm
Hg
RR-norm
mI/mm
1. "Regular"
2. High sodium dialysate
2.19 2.16
(0.97—5.97)
3.30 1.78
14.25 3.42
(8—19.02)
15.29 4.02
3. High initial ultrafiltration
(1.12—5.96)
1.81 1.43a
(9.37—21.53)
21.11 ÷ 497b
4. High initial ultrafiltation
(0.85—4.65)
3.12 l.87
(12.93—26.26)23.06 594l
-
plus high sodium dialysate (1.48—6.45) (14.22—30.51)
P < 0.05 (CI 0.106 to 2.52)
< 0.05 (Cl 0.101 to 3.79)
It is concluded that high dialysate sodium concentration facilitates refilling
during regular and high ultrafiltration by increasing the CFC; it seems
most appropriate during high ultrafiltration in order to avoid intravascular
volume depletion.
Quantification of urea extraction during hemodialysis (HD) by urea
kinetic modeling and simplified dialysate collection. A. Knoflach, C.
Nadig, and U. Binswanger, Universitdtsspital Zurich, Zurich, Switzerland.
Urea removal during HD (3 hours, polysulfon filter F60/F80) was calcu-
lated from single pool variable volume kinetic modelling. It was compared
to dialysate urea recovery described from 2 concentration measurements
obtained at the beginning and the end of the treatment; the median log
concentration was multiplied by the dialysate flow rate. In conclusion, very
similar urea extraction was observed by the 2 methods employed, yielding
comparable distribution volume and generation rate of urea when com-
bined with pre- and post-treatment serum concentrations. From a practi-
cal point of view, blood side modeling affords less chemical analysis.
Prostaglandins are not implicated in the hypoxemia-induced renal
dysfunction of the newborn rabbit. L. Ballèvre, M. Thonney, D. Mosig, and
f-P. Guignard, Service de pediatric, CHUV Lausanne, Switzerland. The
prostaglandins (PG) are potent vasodilators synthesized from membrane
phospholipids by the cyclooxygenase pathway. The PG locally produced in
the kidney, one of the most active PG-producing tissue in the body, have
been recognized to modulate renal blood flow (RBF) and glomerular
filtration rate (GFR), particularly under conditions where vasoconstrictor
systems are activated. Hypoxemia, by stimulating vasoactive systems such
as renin-angiotensin system and adenosine, could thus implicate the renal
PG system in the hypoxemia-induced pathophysiological changes. The
present study was performed in anesthetized and mechanically-ventilated
newborn rabbits to define whether endogenous PG could blunt the
hypoxemia-induced renal vasoconstriction. Clearances of inulin and PAH
were used as indexes of GFR and RBF, respectively. Arterial pressure
(MAP) and heart rate were continuously recorded. Blood gas analysis
were frequently performed throughout the experiments. In group 1 (N =
9), acute hypoxemia (PaO, 43 mm Hg) was induced in 30 mm by a gas
mixture of 10% 02 and 90% N2 and a 60-minute clearance was thereafter
performed. Hypoxemia significantly decreased renal blood flow (RBF) by
17 7%, glomerular filtration rate (GFR) by 11 6% and MAP by 11
2%. The renal vascular resistance (RVR) rose by 11 8%. In a second
group (N = 8), indomethacin (2 mg/kg) was administered intravenously
and two 60-minute clearance periods were obtained. This group was used
to assess the role of PG in renal hemodynamics during basal conditions.
When compared to the control period indomethacin significantly de-
creased RBF by 45 3%, GFR by 46 4% and urine flow rate (UF) by
38 5% and increased renal vascular resistance (RVR) by 57 9%.
Acute hypoxemia (Pa02 43 mm Hg) was induced in 8 additional
newborn rabbits at the end of the first clearance period following the
injection of indomethacin, in order to define whether the hypoxemia-
induced renal changes involve endogenous PG. In this group, hypoxemia
significantly decreased RBF by 51 6%, GFR by 48 7% and increased
RVR by 84 23%. These alterations were greater than those observed in
group 1 but when comparing percent changes from previous clearance, no
change was found between group 1 and 3. The present results suggest that
1428 Abstracts
(1) endogenous PG play an important role in the control of renal
hemodynamics of newborn rabbits during basal conditions, and (2) the PG
system is not implicated in the pathogenesis of the hypoxemia-induced
renal alterations.
Role of nitric oxide in the hypoxemia-induced renal dysfunction of the
newborn rabbit. L. Ballèvre, M. Thonney, D. Mosi and J-P. Guignard,
Seivice de Pédiatrie, CHUV Lausanne, Switzerland. Nitric oxide (NO) is a
very small and lipophilie molecule that accounts for the biological
properties of endothelium-derived relaxing factor (EDRF). NO is a
signaling molecule in blood vessels, where a continuous synthesis from
endothelial cells diffuses through the underlying smooth muscle leading to
vasorelaxation and modulating the vascular tone. Its role in the control of
renal function has been well described in basal conditions. The present
study was thus performed in anesthetized and mechanically-ventilated
newborn rabbits to define whether endogenous NO locally produced in
the kidney could blunt the hypoxemia-induced renal dysfunction. Clear-
ances of inulin and PAH were used as indices of glomerular filtration rate
(GFR) and renal blood flow (RBF), respectively. Mean arterial blood
pressure (MAP) and heart rate were continuously monitored. Each animal
acts as is own control. Blood gas analysis were frequently performed
throughout the experiments. In group I (N = 9), acute hypoxemia (Pa02
43 mm Hg) was induced in 30 minutes by a gas mixture of 10% 02 and
90% N2 and a 60 minute clearance was thereafter performed. Hypoxemia
significantly decreased RBF by 17 7%, GFR by 11 6% and MAP by
11 2%. The renal vascular resistance (RVR) rose by 11 8%. A second
group of 9 animals was administered L-NAME, a NO synthesis inhibitor,
to determine the role of NO in regulating the hemodynamics of the
immature kidney in physiological conditions. L-NAME significantly in-
creased RVR by 31 9% and decreased RBF and GFR by 20 6% and
13 5%, respectively. At the dose used, no change in MAP and heart rate
was reported. Acute hypoxemia (PaO2 45 mm Hg) was induced in 12
additional newborn rabbits during L-NAME infusion in order to define
the role of NO in the renal hypoxemia-induced dysfunction. The alter-
ations of renal hemodynamies observed in group 3 (L-NAME + hypox-
emia) were greater than in group 1 (hypoxemia). During L-NAME
infusion, hypoxemia significantly decreased RBF by 35 3% and GFR by
30 4%, and increased RVR by 54 8%. These alterations were also
greater than the addition of each effect alone observed in groups 1
(hypoxemia) and 2 (L-NAME). The present results suggest that: (1)
endogenous NO plays a significant role in maintaining the basal perfusion
of the immature kidney; (2) NO synthesis is not altered by acute
hypoxemia and is opposing to the hypoxemia-induced renal dysfunction of
the immature newborn kidney.
Role of bradykinin in the vasoregulation of the developing kidney. P.
TOth-Heyn and f-P. Guignard, Service de Pédiatrie, Unite de Néphrologie,
CHUJ/ Lausanne, Switzerland. The renal kallikrein-kinin system (KKS)
has been recognized as a paracrine regulator of renal function. The activity
of this system exhibits developmental changes during the neonatal period
that were found to correlate with the renal hemodynamic changes
occurring at the same time. The exact physiological role of the KKS in the
immature kidney has, however, never been investigated. In order to clari'
the functional importance of the renal KKS, the effect of the bradykinin
B2 receptor antagonist Hoe 140 on the immature kidney was investigated
in 10 newborn rabbits. This antagonist was found to inhibit the hypoten-
sive effect of intraarterial bradykinin for at least two hours in our
experimental model. The clearances of inulin and PAH were used to
assess glomerular filtration rate (GFR) and renal plasma flow, respec-
tively. Subcutaneous injection of 300 jsg/kg Hoe 140 caused a slight but
progressive fall in arterial blood pressure (control 30.3 0.9, 1 hr 28.9
1.1, 2 hr 28.3 1.0 mm Hg). The renal vascular resistance increased
(control 2.05 0.05, 1 hr 2.12 0.06, 2 hr 2.27 0.07 mm Hg/ml/kg*min)
resulting in a decrease in renal blood flow (control: 15.0 0.7, 1 hr 13.8
0.6, 2 hr: 12.6 0.5 ml/kg*min). GFR did not change significantly, while
the filtration fraction increased (control 15.9 0.8, 1 hr 16.7 0.6, 2 hr
18.0 0.8%). These hemodynamic changes indicate preferential efferent
arteriolar vasoconstrietion in accordance with the described dilator effect
of bradykinin on the postglomerular arterioles of the rabbit. A striking
increase in urine flow rate (control 61 7, 1 hr 70 6, 2 hr 86 7
,&Ll/kg/min) and potassium excretion was observed, which changes are in
contrast to the known diuretic properties of bradykinin. The present
results indicate that the KKS is a physiological regulator of renal
hemodynamics in the immature kidney. Bradykinin has a pronounced
vasodilator effect on the efferent arteriolar tone; however, it does not seem
to produce sustained systemic vasodilation under basal conditions. The
newborn rabbit is the first model where a bradykinin antagonist causes
changes in renal function without prior stimulation, suggesting a more
important role for the KKS during renal ontogeny as compared to later
mature stages.
Outcome of pediatric patients with chronic renal failure and end-stage
renal disease. Report from a multicenter study. K Scharer, J. Rosenkranz,
E. Bonzel, M. Bulla, G. Offner, U. Querfeld, and E. Reichwald-Klugger,
Universitats-Kinderkliniken Heidelberg, Essen, Münster, Hannover, Köln,
Germany. In the early 1970's maintenance dialysis (D) and renal trans-
plantation (TX) were regarded as experimental procedures in children
and especially in infants. In the meantime, considerable experience with
renal replacement therapy in this age group has accumulated, as docu-
mented by the regular reports of the Paediatrie EDTA Registry. To obtain
more detailed information, mainly on the psychosocial outcome of
pediatric patients, a longitudinal multicenter study was started in 5
German pediatric nephrology centers in 1987. The main aim of the study
was to assess if more intensified psychosocial care is able to improve later
rehabilitation. The data were regularly updated. Results on selected
medical and psychosocial variables obtained in 547 patients until the end
of 1993 are reported. During this time 38% of patients were on conser-
vative treatment, 9% on HD, 10% on PD and 43% had a TX. At last
assessment 42% had one or more disabilities; 6% were dead. From 1987
to 1993, there was a significant increase of patients aged 0 to 12 years and
a decrease of older patients (from 20 to 14% in patients >19 years).
Kindergarten attendance rose to 82% and school attendance to 100%;
19% attended school for disabled children; 12% left school without
graduation. Among patients aged  17 years who had left school and had
not yet entered professional life, the proportion engaged in vocational
training increased from 52% in 1987 to 83% in 1993. Occupational
degrees were obtained by 59% vs. 26%. In patients not attending school or
vocational training, employment was reported in 77% vs. 43%. The
proportion of patients 18 years living independently has remained
constant (10%) and is lower than in the normal population. In an
additional single center study of 43 pediatric patients aged 18—30 years
who had been transferred for >1 year into adult units (59% TX), we noted
56% living on their own or with a partner/spouse and 76% with vocational
graduation; 7 patients had their own children. In conclusion, the degree of
late rehabilitation in pediatric patients with chronic renal failure or ESRD
in regard to schooling, vocational performance and employment has
improved over the last years, possibly related to intensified psychosocial
care, but is still insufficient.
Hypochromic red blood cells (HRBC) and erythrocyte Linc-protopor-
phyrin (ZPP) are not accurate indicators of iron deficiency in hemodial-
ysis patients starting erytbropoietin therapy. E. Descombes, G. Vogel, J.
Rosman, and f-P. Wauters, Division of Nephrology, CHUI/, Lausanne,
Switzerland. It has been suggested that the percentage of hypochromic
RBC (% HRBC) or ZPP concentration may be more accurate indicators
of iron deficiency than transferrin saturation (TfSat) or serum ferritin
(SFE). To compare the relative usefulness of these parameters we studied
their evolution in 15 anemic (mean SD hemoglobin, 79.3 6.3 g/liter)
HD patients (10 F/5 M, mean age 51 13 years) starting erythropoictin(EPO). The study lasted 16 weeks. During the first 8 weeks EPO was
prescribed subcutaneously at a starting dose of 2 X 50 U/kg/week. Since
week 9 an intravenous (iv.) iron supplement of 100 mg/week was also
given. Target hemoglobin (Hb) and hematocrit (Ht) levels were 100 to 120
g/liter and 30 to 35%, respectively. All the patients except one reached
these targets at the end of the study. The EPO dose was increased in none
of the patients while it had to be diminished in four. Eight patients
reached the target Hb/Ht values during the first 8 weeks (i.e. before any
iron supplement) and were considered early responders. The studied
laboratory parameters were measured every two weeks. During the first 8
weeks of the study a majority of the patients developed a marked iron
deficiency as evidenced by a TfSat <15% (in 13/15 patients) and sFE
levels <50 g/liter (in 7/15 patients). %HRBC and ZPP failed to
accurately identify these patients of being clearly iron deficient according
to these conventional criteria, and also could not differentiate the early
from the late responders. When early and late responders were further
compared, a significant difference was found only for TfSat with higher
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values in early responders either before (16 7.0% vs. 10.2 5.6%, P <
0.01) and after (18.3 8.9% vs. 12.9 7.7%, P < 0.02) i.v. iron
supplementation. It's worth noting, however, that 4 early responders
corrected their anemia despite TfSat levels consistently between 10% and
15%. In conclusion, (a) our data do not confirm the statement of previous
studies suggesting that %HRBC and/or ZPP may more accurately identify
iron deficient patients than TfSat and sFE; (b) before the start of EPO
therapy early responders tended to have sFE >100 pg/liter and TfSat
>15%; (c) late responders had lower TfSat levels than early responders
and frequently developed a rapid and consistent fall of the TfSat to <10%
after the first 4 weeks of EPO therapy.
Rescue treatment by local irradiation of renal allografts after unsuc-
cessful rejection therapy. C. Nadig, U Binswanger, T. Weinreich, and W.
Magdeburg, Nephrologie, Universitatsspital, Zurich, Switzerland. A retro-
spective study was performed to evaluate efficacy and side-effects of local
X-ray therapy, 3 X 150 cGy, in refractory renal allograft rejection. 21
patients were observed from September 1992 through May 1995. The
basal immunosuppressive treatment was prednisone, azathioprine and
cyclosporine A. Rejection therapy included prednisone pulses, ATG(Fresenius), and/or ATGAM (Upjohn) and OKT3 in all cases. Results
were as follows:
Successful response to
X-ray therapy
Unsuccessful response
to X-ray therapy
Mean Sr in rmol/ Mean Sr in jmol/
liter SD liter SD
Time N (mm—max) N (mm—max)
Minimum value after 16 214 78(135—405) 5 178 48 (109—235)
previous rejection
therapy (OKT3)
Maximum value 16 319 83 (184—461) 5 355 155 (220—567)
before X-ray
therapy
30 days after X-ray 16 234 62 (144—365) 3U 429 294 (241—767)
therapy
1 year after X-ray 277 163 (141—669) 0
therapy
time interval, days 16 136 101 (35—377) 5 70 33 (42—117)
transplant.-X-ray
therapy
Immunosuppression 16 5
Prednisone, mg/ 19 10 (10—40) 26 9 (10—30)
day
Azathioprine, mg/ 55 16 (25—75) 63 18 (38—75)
day
Cyclosporine A, 234 83 (100—400) 200 61(100—250)
mg/day
HLA mismatches 16 4.1 0.9 5 3.6 0.5
U 2 patients rejected transplants by day 30, maintained on dialysisb2patients rejected, on dialysis; 1 patient died; 4 observed for less than
1 year
"4 patients rejected transplant by 1 year, maintained on dialysis; 1
patient died
No side-effects of the therapy were observed. We conclude that local
irradiation seems to be an innocuous treatment mode, followed by a high
rate of stable transplant function that warrants further study in cases of
refractory rejection.
Fluoroquinolone associated tendon rupture and bilateral tendinitis in
a hemodialysis patient and two renal transplant recipients. F. Cattaneo,
M. Sema, and R. Stoller, Department of Nephrology, University Medical
Clinic, Inselspital and Phannacovigilance-Centre, Intercantonal Office for the
Control of Medicines, Berne, Switzerland. Tendon rupture and tendinitis are
rare but well-documented adverse reactions of the fluoroquinolones, a
review of 100 spontaneous reports from France having recently been
published by its pharmacovigilance centre. Renal transplant recipients and
patients with renal failure seem to be at higher risk for this complication.
We describe 3 such patients treated with adequate doses of fluoroquino-
lones, observed in our department within the last 6 months. Patient A, is
a 37-year-old man with diabetic nephropathy, on hemodialysis since 16
years, who suffered spontaneous rupture of the quadriceps tendon under
treatment with ciprofloxacin (and other antiinfectives) for 2 months. Two
male renal transplant recipients (patient B, aged 68 and patient C, aged 55
years) developed bilateral tendinitis (B of Achilles tendon and C of
extensor hallucis longus) within two to three days after starting fieroxacin
(B) or ciprofloxacin (C). They fully recovered within a month after
stopping the drug. Both patients had a long-standing history of renal
disease with cadaveric kidney transplantation performed 14/9 years ago. In
both, renal function was strongly impaired due to chronic rejection
(creatinine clearance 15 and 22 mI/mm). Their immunosuppressive regi-
men consisted of prednisone 15 and 12.5 mg per day, azathioprine 125/125
mg per day, respectively, and cyclosporine 125 mg in patient C. The
incidence of tendon complications due to fluoroquinolones in renal
transplant and hemodialysis patients as well as the importance of long-
standing renal impairment, the immunosupressive regimen, the cumula-
tive exposure to quinolones and of metabolic factors (hyperlipidemia,
diabetes) remain to be determined. Precautions should be taken when
prescribing fluoroquinolones to these patients, the drugs stopped imme-
diately when symptoms of tendinitis occur so that measures can be taken
to prevent rupture.
New analogs of 1,25-(OH)2D3 to blunt secondary hyperparathyroidism
in uremia: An experimental study. K Lippuner, R. Perrelet, MR. Usko-
kovic, and Ph. Jaeger, Medizinische Universitdtspoliklinik, Bern, Switzerland
and Hoffinann-La Roche Inc., Nutley, New Jersey, USA. The effect of
calcitriol in the treatment of secondary hyperparathyroidism (SHPTH) in
patients with chronic renal failure is often limited by development of
hypercalcemia. Therefore, effort has been placed into the development of
analogs of calcitriol to blunt SHPT without hypercalcemia. In a first series
of experiments we tested the calcemic response to new analogs of calcitrinl,
e.g. 1 ,25-(OH)2-16-ene-D3 (ROl), 1,25-(OH)2-16-ene-23-yne-D3 (R02),
1,25-(0fl)2-26,27-hexafluoro-16-ene-23-yne-D3 (R03) and 1,25-(OH)2-
16-ene-23-yne-26,27-hexa-fluoro-19-nor-D3 (R0-4), compared with 1,25
(OH)2D3 (ROC) and with vehicle (NaCI) alone. Four days after parathyroid-
ectomy (PTX) 38 female Wistar rats (weight 257 4 g) daily received either
250 pmol of one of the 5 compounds or NaCI given i.p. for 8 days. Criterion
for successful PTX was a serum ionized calcium concentration (Ca) of less
than I mmol/liter after overnight fast. Blood was drawn daily for Ca + and
plasma phosphorus (P) (mmol/liter). Results of the PTX experiment at day 0
and at 8 are given below.
Day NaCl (N = 6) R0C (N = 7) ROl (N = 7)
CaCa
P
P
0
8
0
8
0.95 0.05
0.99 0.04
3.59 0.18
4.09 0.24
1.02 0.04
1.79 0.03U
3.59 0.06
2.53 0.17a
1.06 0.05
1.36 0.03"
3.71 0.15
3.21 0.l8'"
R02 (N = 6) R03 (N = 6) R04 (N = 6)
Ca 1.06 0.05 1.04 0.09 0.97 0.05Ca 1.35 0.04 1.44 0.O3'" 1.25 0.04""
P 3.67 0.14 3.35 0.13 3.43 0,17
P 3.53 0.14" 3.30 024hd 3.56 0.19'
up < 0.001 vs. NaCl, hp < 0.01 vs. MaCI, C < 0.001 vs. ROC, dp <
0.01 vs. ROC, P < 0.05 vs. ROC (ANOVA). Data are mean SEM.
In a second set of experiments we used the model of 5/6 nephrectomy
(NTX) to generate SHPTH and to test the effect of those compounds on
Ca and serum intact PTH (iPTH) concentrations: 3 weeks after 5/6
NTX, 36 (6/group) uremic rats received daily i.p. injections of the
aforementioned compounds at the dose of 250 pmol/day during 28 days.
At days 0, 14 and 28, blood was assayed for Ca + and IPTH. At that dose,
ROC, R02 and R04 were effective in suppressing iPTH. Therefore we
selected these 3 compounds for a dose-response experiment in uremic
rats. ROC and R04 were given at a dose of 125 and 250 pmol/day,
whereas R02 was applied at doses of 250, 500 and 1000 pmol/day. There
were no intergroup differences of Ca ' or iPTH concentrations at
baseline. Relative changes in percent of baseline of these parameters over
the 28 days study period are given in the table.
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NaCI ROC 125 pniol ROC 250 pmol R02 250 pmol
Ca' —2.9 1.5 9.7 2.3 20.7 1.9° 5.7
ziPTH 365.7 182.3 —71.8 17.7° —97.9 1.0 —46.9 20.0°
R02 500 pmol R02 1000 pmol R04 125 pmol R04 250 pmol
CaC 4.4 2.4°' 20.2 2.9 12.6 1.6k 12.1 6.3"
LiPTH —81.1 9.7° —95.7 1.2' —85.8 7.3' —25.1 73.4
'P < 0.001 vs. NaCl, h P < 0.005 vs. NaCI, P < 0.001 vs. ROC 250,
"P < 0.005 vs. ROC 250 "P < 0.001 vs. R02 1000 (ANOVA). Data are
mean SEM.
In conclusions, evidence is provided that new analogs of calcitriol elicit
smaller responses of Ca"' level than the native compound. In uremic rats
it is possible to trigger a smaller elevation of Ca" with R02 than with
ROC for a similar PTH-suppressing effect.
Pregnancy in renal disease: Experience of a single Swiss Center. C.
Ferrier, L. Taminelli, Y Vial, and J-P. Wauters, Division of Nephrology and
Department ofjnecoIogy-ohstetric, University Hospital, Lau.sanne, Switzer-
land. The successful outcome of pregnancy in women with renal disease is
not only related to the clinical and histological diagnosis, the kidney
function and blood pressure (BP) level prior to pregnancy, hut also
depends from the long standing experience of a multidisciplinary team.
This retrospective analysis was performed to evaluate the prevalence of
gestational hypertension (GH), preeclampsia (PE), prematurity (PREM)
and intrauterine growth retardation (IUGR) in women with underlying
renal disease who were followed in our units between 1980 and 1995.
Gestational hypertension was defined as a BP  140/90 mm Hg with an
increase of at least 15 mm Hg in diastolic BP. PE included women with
OH and proteinuria >300 mg/24 hr or a doubling of early gestation
proteinuria. IUGR was defined as a birthweight less than the 10th
percentile for gestation and PREM as a delivery at less than 37 weeks
gestation. Thirty-five pregnancies occurred in 19 women with renal disease
(N = 12) or kidney transplant (N 7). The renal diagnosis included
primary and secondary glomerulonephritis (N = 3), diabetic nephropathy(N = 4) and refiux nephropathy (N = 5). Overall fetal loss was 13 (37%)
of which 5 (38%) were therapeutic abortions. In the remaining 22
pregnancies, who reached fetal viability and/or at least 22 weeks of
gestation, GH alone complicated 14% and PE 36% of these pregnancies.
Renal function declined in 32%. IUGR and PREM rate were 23% and
59%, respectively. There were 2 (9%) stillbirths. Six pregnancies took
place in women with plasma creatinine (P'r) >0.90 mmol/liter and ten in
women with 24 hour proteinuria >300 mg in early gestation. The highest
prevalence of PE (50%) was recorded in the group of women with
proteinuria, while PREM rate was similar in the groups with elevated (r
and proteinuria (80% and 83%, respectively). Comparison of women with
renal transplant versus women without renal transplant revealed a higher
ineidenee of PREM (71%), but a lower PE rate (14%) in renal transplant
recipients. Overall, a greater prevalence of fetal and maternal complica-
tions occurred in patients with preexisting proteinuria. However, pre-
pregnancy assessment and a careful monitoring during pregnancy can
improve both maternal and fetal outcome.
Utilisation dii moniteur d'urée pour quantifier de manière suivie
l'efficacité de Ia dialyse. G. Vogel, D. Teta, et .1-P. Wauters, Division de
Nephrologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzer-
land. A Ia suite de Gotch et Sargent, Ia mesure du Kt/V (clearance
totale/volume de distribution de l'urée) et Ic PCR (protein catabolic rate)
sont devenus des instruments précieux pour apprécier l'efficacité du
traitement par hémodialyse chronique. Jusqu'ici la quantification math-
ématique de Ia dialyse se faisait a partir de données indirectes et
imprécises concernant Ic filtre de dialyse (UK) ou a partir de Ia mesure
(peu commode) du transfert de masse par recueil de Ia totalité du dialysat
(DDQ). Récemment Ia mesure en continu de Ia concentration en urée du
dialysat permet l'extrapolation mathématique de Kt/V et de PCR. Cette
méthode devrait être aussi precise que DDQ sans ses inconvénients. Sa
simplicité de misc en oeuvre en ferait done une méthode de premier choix.
Nous avons mesuré par Ic moniteur d'urCe l'effieacité de Ia dialyse chez
tous les patients traités en centre et repbté ces mesures a 3 et 6 mois. La
premiere mesure de Ia einétique de I'urée nous a permis de elasser nos
patients en 4 groupes. En fonction des résultats des eonscils dietétiques
et/ou des modifications des paramètres de dialyse (augmentation du debit
sanguin, changement du filtre, prolongation de Ia durCe de dialyse) ont etC
introduits. Les résultats sont donnés par Ia moyenne l'écart-type.
N. 1 Kt/V PCR N. 2 Kt/V PCR
Total 83 1.35 0.89 70 1.32 0.94
GROUPE 1 21 0.95 0.75 16 1.04 0.86
Kt/V < 1.2 PCR < 1.0
GROUPE 2 28 [.56 0.76 23 1.5 0.85
Kt/V > 1.2 PCR < 1.0
GROUPE 3 11 0.99 1.07 10 1.04 1.08
Kt/V < 1.2 PCR > 1.0
GROUPE 4 23 1.63 1.10 21 1.48 1.05
Kt/V > 1.2 PCR > 1.0
N. 3 Kt/V PCR
Total 41 1.29
0.40
0.93
0.22
GROUPE 1 12 1.07 (1.90
Kt/V < 1.2 PCR < 1.0
GROUPE 2 13 1.37 0.69
Kt/V > 1.2 PCR < 1.0
OROUPE 3 6 1.08 1.02
Kt/V < 1.2 PCR> 1.0
GROUPE 4 12 1.31 1.02
Kt/V > 1.2 PCR > 1.0
Ces résultats conduisent aux conclusions suivantes: Ic moniteur d'urée
permet Ia quantification de Ia dialyse de manière simple et repetée, il
permet Ia misc en place de mesures thérapeutiques pour augmenter Ia
qualité de La dialyse. Enfin il entraine l'adhCsion des infirmières et des
patients a Ia misc en route de ces mesures.
Clinical presentation and outcome of 14 patients with the diagnosis of
renal cholesterol emboli. D. Teta, F. Steinhauslin, C. Vogel, JP. Wauters,
Division de néphrologie, Centre Hospitalier Universitaire Vaudois (CHUI'9,
Lausanne, Switzerland. It is generally recognized that renal cholesterol
emboli (RCE) is a presumly rare condition, occurs more frequently in
patients with underlying vascular disease often after catheter procedures,
and presents with acute renal failure (ARF), poor prognosis and high
mortality rate. Whether milder forms leading to partial or complete
recovery or renal function may occur is unclear. Therefore, between 1992
and 1995, we systematically screened patients presenting with acute or
chronic renal failure of unknown origin in order to point out this diagnosis
and evaluate possible prognostic faetors for renal outcome. The following
clinical and/or histological diagnostic criteria were retained in 14 cases (13
males, 1 female; age range: 50—76 years, mean 63 years): presence of
typical cutaneous lesions as purple toes (4) or livedo reticularis of lower
limbs (6), retinal cholesterol emboli on fundoscopy (9), blood eosinophil
count >500/mm3 (11), elevated erythrocyte sedimentation rate above 50
mm (13), negative antiDNA and ANCA antibodies (10), deposits of
cholesterol crystals in the lumen of small arterioles obtained from kidney
or skin tissues (3). Of the 14 patients, 10 (71%) had a history of chronic
renal failure (CRF) and in the 8 weeks preceeding the diagnosis 10 (71%)
underwent an invasive vascular procedure (7 cardiac eatheterisms, 2 renal
arterial angioplasties and one aortic vascular surgery). Spontaneous forms
of RCE were observed in 4 (29%) patients. Thirteen (93%) patients
presented with ARF and only one with CRF and nephrotic range
proteinuria. Irreversible renal damage, necessitating dialysis, occurred in 5
of 10 patients with previous CRF and one patient of this group died of
aneurysmal aortie rupture. None of the 4 patients with previously normal
kidney function reached end-stage renal failure, and one of these died
following myocardial infarction. Stabilization or partial recovery of renal
function was observed in all the patients with previously normal and in
50% with previously abnormal renal function. History of invasive vascular
procedures does not affect the prognosis by itself since 3 (50%) patients
with history of CRF and none of 4 subjects without previous CRF reached
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end-stage renal failure. These results indicate that if the diagnosis of RCE
is accurately recognized, low mortality rate and favorable outcome may be
frequently observed. Previous CRF, however, strongly increases the rate
of irreversible kidney failure.
Effect of 1,25-vitamin D1 (1,25) and a synthetic vitamin D analogue (KB
1060) on the expression of adhesion molecules in mouse renal tubular
cells (MCT). Th. Weinreich, C. Booy, R. Wüthrich, U. Binswanger, Abttei-
lung für Nephrologie, Universitätsspital, Zurich, Switzerland. Proximal tubu-
lar cells (PTC) play an important role in immune-mediated interstitial
renal disease and transplant rejection, that is, by expression of adhesion
molecules as ICAM-1 and VCAM-l. Recently 1,25 was shown to provide
immunosuppressive effects in vitro and in vivo. In addition, 1,25 inhibits
the proliferation of proximal tubular cells. To test the hypothesis that 1,25
effects the immunoregulatory function of PTC we investigated the effect of
1,25 and KH 1060 on the expression of ICAM-l and VCAM-1 in MCT.
Adhesion molecule expression was assessed by immunofluorescence stain-
ing (qualitative) and a cell-ELISA technique (quantitative); all experi-
ments were performed under serum-free conditions. No staining for
ICAM-1 and VCAM-1 was observcd in MCT treated with medium only or
after 24 hour exposure to 1,25 (10- M). After incubation with TNF (50
ng/ml) and IFN-y (100 U/mI) both ICAM-l and VCAM-1 could he
demonstrated in 95% of MCT. Prcincubation with 1,25 (24 hr) did not
alter the pattern of adhesion molecule expression to TNF + IFN-y. The
results of the cell-ELISA are given as OD (mean SI)).
Solv. 1,25 (10 M) 1(1-I 1060 (10-v M)
ICAM-1 49 18 89 36 75 13
VCAM-1 39 20 46 25 46 12
TNF + IFN TNF + IFN
TNF + IFN + 1,25 + KH 1060
ICAM-l 887 42 808 52 746 10
VCAM-1 756 84 731 3 763 13
Treatment with 1,25 or KH did not result in significant differences to
untreated controls neither with or without TNF/IFN-y stimulation. In
conclusion, 1,25 and the synthetic vitamin D analogue KH 1060 in
pharmacological doses have no effect on the expression of the cell
adhesion molecules ICAM-1 and VCAM-1 in mouse proximal tubular
cells.
Matrix metalloproteinase inhibitor Ro 3 1-9790 and mesangial cells:
Inhibition of 72-kDa type IV collagenase and cell proliferation. K Niggli,
M. Lukes, and H-P. Marti, Abteilung für Nephrologie, Departement Innere
Medizin, Inselspital, Bern, Switzerland. 72 kDa type IV coflagenase has
been shown to induce or to sustain an activated, proliferative mesangial
cell (MC) phenotype. Therefore, we speculated that the matrix metallo-
proteinase (MMP) inhibitor Ro 31-9790, a hydroxamie acid derivative,
may have an effect not only on 72 kDa type IV eollagenasc but also on MC
proliferation. For our studies, a strain of rat mesangial cells expressing 72
kDa type IV eollagenase as the sole MMP was used. Conditioned media
of suheonfluent MC were subjected to quantitative zymography. Exposure
of gelatin containing zymograms to Ro 3 1-9790 lead to a dose-dependent
decrease in the intensity of zones of lysis with complete inhibition of
gelatinolytie activity at I jzM. Furthermore, as shown by a fluorescent
assay, incubation of MC culture supernatant with Ro 31-9790 in concen-
trations of 0.1 /LM and above demonstrated significant inhibition of the
activity of 72 kDa type IV collagenase. For cell culture experiments,
subeonfluent MC were propagated in the presence of Ro 31-9790 for up
to 72 hr. Ro 3 1-9790 in concentrations of 1 to 100 fLM caused a
dose-dependent inhibition of cell proliferation. At the maximal dose,
thymidine incorporation decreased to about 35%, which was confirmed by
direct cell counting. Almost identical results were obtained utilizing cell
culture medium containing 1% or 10% FCS. Viability of MC was not
affected as shown by light microscopy and trypan blue exclusion. In
conclusion, inhibition of MC 72 kDa type IV eollagenase and MC
proliferation by synthetic MMP inhibitors may open up new perspectives
for the therapy of mesangial cell-derived forms of glomerulonephritis.
Up-regulation of renal phospholipase A2 (PLA2) group II in rats with
liver cirrhosis (LC). B.S. Vishwanath, G. Escher, F.i Frey, .1. Reichen, and
B.M. Frey, Ahteilungfiir Nephrologie und klinische Pharmakologie, Inseispi-
tal, Bern, Switzerland. Maintenance of renal function in LC requires
increased synthesis of araehidonic acid derived prostaglandin metabolites.
The purpose of the present study was to establish whether the first enzyme
of the cascade of prostanoid synthesis, the PLA2 is altered in LC induced
by bile duet ligation. The mRNA of group I and II PLA2 were measured
by RT-PCR using GAPDH as an internal standard and the activity of
PLA2 was determined in kidney and liver tissues from rats without (N =
5) and with LC (N = 7) as previously described. Total RNA (j.Lg/g tissue)
was lower by one third in both, kidney and liver tissues in LC than in
controls (P < 0.005). Whereas mRNA of PLA2 group I was not detectable
in kidney and liver tissues in animals with and without LC, transcription of
PLA2 group II was increased in both organs in LC. The increase in group
II mRNA was reflected by a corresponding increase in PLA2 activity [LC
vs. controls, kidney tissue (x SD): 2.0 0.8 vs. 0.9 0.2 nmol fatty
acid/mg protein/mm, P < 0.01; liver tissue: 12.1 5.0 vs. 4.4 1.7 nmol
fatty acid/mg protein/mm, P < 0.0021. In conclusion, in LC PLA2 group II
is increased and therefore contributes to the enhanced prostaglandin
synthesis in LC.
Down-regulation of renal 1l3.hydroxysteroid dehydrogenase (lifi.
OHSD) in rats with liver cirrhosis (LC). G. Escher, B.S. Vishwanath, B.M.
Frey, J. Reichen, and F.J. Frey, Abteilung für Nephrologie und klinische
Pharmakologie, Inselspita4 Bern, Switzerland. Traditionally urinary loss of
potassium is attributed to increased concentrations of aldosterone in LC.
Besides aldosterone, endogcnous glucocorticoids might also exhibit mm-
eralocorticoid effects, provided the activity of the 11/3-OHSD is impaired;
the 11/3-OHSD converts 11/3-OH- to inactive Il-keto-steroids, thus pre-
venting promiscuous access of glucocorticoids to mincralocortieoid recep-
tors (MR) in healthy mammals. To establish whether the oxidation of
11/3-OH-steroids is impaired in LC, we investigated the impact of LC
following bile duct ligation on the transcription assessed by RT-PCR using
GAPDH as an internal standard and on the activity of 11 /3-OHSD2 (renal,
NAD dependent, high affinity, "MR gate keeper" isozyme) and of
11f3-OHSD1 (liver, NADP dependent, low affinity isozyme) in kidney and
liver tissues. In liver tissue the mRNA ratio of 11/3-OHSDI/GAPDH was
decreased (3.2 0.6 vs. 5.6 1.5, x SD, P < 0.007) and the
corresponding activity assessed by the conversion of corticosteronc into
dehydrocorticosterone was reduced (35.1 4.4 vs. 42.0 5.4 pmol/pg/hr,
P < 0.035) in LC. In kidney tissue similar changes for 1Ip-OHSD2 were
observed (LC vs. controls, mRNA 11p-OHSD2/GAPDH, 1.6 0.4 vs.
2.6 0.9,P <0.046; activity, 1.5 0.4 vs. 2.5 0.3 fmol/jrglhr,P <0.001).
In conclusion, in LC the MR protecting 11/3-OHSD2 isozyme is down-
regulated in the kidney and by that mechanism allows endogenous
glucocortieoids to act as mineraloeorticoids.
The Solute Removal Index (SRI)—A flawed marker of dialysis ade-
quacy. D.E. Uehlinger, Abteilung für Nephrologie, Departement Medizin,
Universität Bern, Switzerland. The SRI has been proposed as a new index
of dialysis adequacy. It is defined as the ratio between the amount of urea
removed and the total body content of urea. The SRI is more easily
calculated than Kt/V and supposedly provides a unified, intuitive basis for
comparing disparate therapies. For intermittent dialysis therapies such as
hcmodialysis, the SRI is detined as the ratio between net urea removal and
the predialysis urea body content. Whereas SRI and Kt/V indices are
numerically identical for continuous therapies such as CAPD, lower SRI
than Kt/V indices arc calculated for hemodialyis. It can easily be seen that
SRI is a conceptually flawed marker of dialysis adequacy when a regular
hemodialysis session is artificially split into two half sessions following
each other immediately. Despite unchanged dialysis adequacy, the total
SRI calculated over the two half sessions exceeds the SRI calculated from
the original session. The SRI fails to describe adequacy of intermittent
dialysis therapies, since the total urea body content decreases during the
observation period and so does the relationship between the amount of
urea excreted and the predialysis urea body content.
Inherited disorders with combined liver and kidney involvement in
children. TJ. Neuhaus, C. Bragger, J. Briner, H. Iselin, E. Leumann,
Universitats-Kinderklinik und Institutfiir Klinische Pathologie, Zurich, Swit-
zerland. Combined liver and kidney involvement is known in a few
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inherited conditions, such as autosomal recessive (and dominant) polycys-
tic kidney disease, nephronophthisis, Meckel-Gruber syndrome, Alagille
syndrome, glycogenosis type 1 and primary hyperoxaluria. We have
observed two further disorders affecting 2 children in 2 separate families.
Two brothers presented with renal-hepatic-pancreatic dysplasia. The first
boy died shortly after birth of lung hypoplasia. Autopsy showed bilateral
multicystic renal dysplasia, hepatic fibrosis and a normal pancreas. His
brother presented with progressive renal insufficiency at 5 months. Pen-
toneal dialysis was started at 14 months. At that time liver enzymes were
elevated and liver biopsy showed fibrosis and dysplastic bile ducts. On
ultrasound, the pancreas was hyperechogenic. Cholestasis developed and
hepatic function deteriorated. At 3.7 years a combined liver-kidney
transplantation was performed. Simultaneously performed renal and liver
biopsies showed multicystic renal dysplasia and progressive biliaiy cirrho-
sis. More than 2 years later renal and hepatic function are normal, and
development is according to age. So far only 23 children with this
syndrome have been reported, and all had died of renal failure within the
first year of life. Two further siblings presented with a novel association of
interstitial nephnitis and primary sclerosing cholangitis. The girl had
pyelonephritis at 5 months. Renal biopsy performed at 16 months because
of persistent proteinunia showed interstitial nephritis and focal destruction
of glomeruli. Renal function deteriorated rapidly and peritoneal dialysis
was started at 1.9 years. Family screening showed hypertension and
progressive renal insufficiency in her 3.9 year old, asymptomatic brother.
Haemodialysis was commenced at 6.5 years. In addition, both siblings
showed slightly elevated liver enzymes (AST >40 U/liter, y-GT >100
U/liter; normal bilirubin and clotting factors). Liver biopsy (girl at 3.5
years, boy at 6.6 years) and endoscopic retrograde cholangiopancreatog-
raphy (girl at 4.9 years, boy at 6.6 years) revealed primary scierosing and
destructive cholangitis. In conclusion, in children with renal disorders, (1)
family screening is important, and (2) a search must be done for liver
involvement. A combined liver-kidney transplantation offers a valuable
therapeutic option.
Prenatal diagnosis of autosomal-recessive polycystic kidney disease
(ARPKD). E. Leumann, A. Schinzel, T Stailmach, J. Wisser, and K Ze,res
Universitats Kinderklinik, Universitats Frauenklinik, Institut für Klinische
Pathologie, Institut für Medizinische Genetik, Zurich, Switzerland; and
institut für Humangenetik Bonn, Germany. ARPKD is an important
hereditary cause of renal cystic disease in children and mostly carries a
grim prognosis. The recent localization of the ARPKD gene on chromo-
some 6 and progress in fetal ultrasonography make early diagnosis now
feasable. The mother of a now 5-year-old son with grossly enlarged
kidneys, chronic renal failure and hepatic fibrosis sought advice during her
second pregnancy. Ultrasound scans at 15 and 19 weeks of gestation
showed bilateral echogenic kidneys of normal size. Haplotype analysis was
done from DNA obtained from chorionic villi and blood of both parents
and the affected sibling, using flanking markers in the region of 6p21-cen.
The fetus carried the maternal disease allele; in the paternal allele, there
was recombination between the informative flanking markers D6S436 and
D6S466. The risk to the fetus of being affected was considered to be high
in view of the echographic findings. The pregnancy was terminated at 21
weeks gestation. The fetal kidneys were macroscopically normal but
showed dilation of the collecting ducts. Proliferation of bile ducts con-
firmed the diagnosis of fetal ARPKD. This is one of the earliest diagnosed
cases of ARPKD. The possiblity of prenatal diagnosis should now be
considered in affected families with documented ARPKD.
Twenty-five years of pediatric dialysis and transplantation in Zurich. E.
Leumann, A. Gamperli, T. Neuhaus, R. Schlumpf and F. La,'iadèr,
Universitäts Kinderklinik und Klinik fur Viczeralchirurgie, Universitatsspital,
Zurich, Switzerland. Between 1970 and 1994, 84 patients were started on
renal replacement therapy (RRT), renal transplantation (TPL) being the
main goal. A total of 45% of the children were aged 10 to 15 years and
14% were <5 yrs at start of RRT; 52 children were treated by hemodial-
ysis and 27 by peritoneal dialysis and 5 underwent pre-emptive TPL. By
December 1994, 75 children had received 99 grafts (3 from live donors), 7
children were still on dialysis, and 2 had died before TPL. Eight patients
were transplanted elsewhere. Actuarial patient survival after the start of
RRT is 88% at 10 years and 75% at 17—25 years. It increased from 91%
(1970—1984) at 5 years after first TPL to 97% (1985—1994). Seven of the
first 10 patients transplanted over 20 years ago are alive. Nine patients
died after TPL, 4 were due to complications after recurrence of the
underlying disease, 2 of viral infections (EBV, CMV) and 1 each of
spinalioma, allergic shock and traffic accident. First graft survival in-
creased from 53% (1970—1984) at 5 years to 72% (since 1985). Main
causes of first graft loss (N = 32) were irreversible rejection (20) and
recurrent disease (7). Somatic development and psychosocial integration
were evaluated in all patients aged >22 years. Patients in group A (Start
of RRT 1970—1979; N = 18) were smaller than those in B (start of RRT
1980—1987; N = 19), men by 4.6 cm and women by 10.2cm. Fewer patients
in A (39%) than in B (62%) were fully employed, and more patients in A
(61%) than in B (37%) lived with their parents. Not only patient and graft
survival, but also social integration has improved over the years. Overall
results clearly justi/ the great efforts involved in RRT of pediatric
patients.
IL-2 for allograft rejection and IL-4 for allograft tolerance: Is it really
that easy? J. Steiger, P. Nickerson, P. Roy-Chaudhuy, W Steurer, G. Thiel,
and TB. Strom, Beth israel Hospital and Harvard Medical School, Boston,
Massachusetts, USA and Division of Nephrology, Kantonsspital Basel, Basel,
Switzerland. An intensive effort has been launched to understand the
T-cell cytokinc programs associated with allograft rejection and tolerance.
We and others have consistently detected intragraft IL-2, IFNy, and the
CTL specific marker granzyme B, proteins and/or transcripts in rejecting
allografts, while IL-4 expression is inconsistently detected. The pattern of
cytokine expression during the period of tolerance induction has been
associated with a dramatic decrease in the expression of the Thi-type IL-2
and IFNy cytokines as compared to acutely rejecting hosts, while in-
creased levels of IL-4 transcripts are often manifest. Based on these
observations it has been suggested that allograft tolerance induction
requires a shift from the Thi cytokine program (IL-2 and IFNy) that is
evident during acute rejection to a Th2 (IL-4 and IL-b) response. To test
the hypotheses that (1) IL-2 expression is necessary for rejection, and (2)
IL-4 expression is necessary for tolerance we transplanted islets from
DBAI2J donors (H2d) into C57B1/6xOLA129 knock out (KO) mice
(H-2"), whose IL-2, IL-4 or IL-2 and lL-4 genes have been functionally
silenced by targeted gene disruption. IL-2 KO mice can reject an allograft
(Table). Although rejection is delayed in IL-2 KO hosts compared to wild
type (WT) recipients, the histologic analysis demonstrates classical rejec-
tion in the grafts of IL-2 KO hosts as a dense CD4+ and CD8+ infiltrate
invades and destroyes the islets. Interestingly, rejection is characterized by
the absence of IL-2 and the presence of IL-4 gene transcripts. However,
IL-4 expression in the IL-2 KO host does not account for the delayed
rejection in these mice as IL-2/4 double KO mice reject islets allografts
with the same tempo as IL-2 KO mice. Moreover, IL-4 expression is not
absolutely required for engraftment as therapy with murine CTLA4/Fc
delays rejection and leads to permanent engraftment in 50% of IL-4 KO
hosts. In conclusion, (1) IL-2 is not required for allograft rejection. (2)
Delayed rejection in IL-2 KO mice is due to the absence of IL-2, not the
unopposed expression of IL-4. (3) While IL-4 may be a marker of
tolerance, IL-4 is clearly not an absolute requirement.
IL-2/IL-
Wild IL-2 IL-4 4 double IL-4 KO +
Model type KO KO KO CTLA4/Fc
IL-2 expression + — + — +
IL-4 expression + + — —
Allogeneic Reject Reject Reject Reject 50% engraftment
transplant
Mean survival 13 days 23 days 12 days 21 days >100 days
time
Lack of evidence for better survival rates of patients treated with
continuous than with intermittent hemodialysis procedures. S.M. Jokob,
F.J. Frey, and D.E. Uehlinger, AbreilungJiir Nephrologie, Deportement Innere
Medizin, Inseispital, Bern, Switzerland. Mortality remains high in critical
care patients with acute renal failure. There are some theoretical advan-
tages of continuous dialysis procedures in comparison with intermittent
therapy. To establish whether these advantages are reflected by a better
outcome (survival rate), we reviewed all published reports about contin-
uous dialysis procedures. No prospective, randomized controlled study
was available from the literature. Therefore we first analyzed all published
studies comparing continuous with intermittent dialysis modalities within
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the same centers using imperfect study conditions (number of studies, N =
15; total number of patients N = 1173). When all patients were analyzed
as a group, multivariate weighted logistic regression analysis revealed a
tendency for better outcome from 1986 to 1993. Treatment modality, age
and Apache II score did not influence the outcome. The analysis of all
available publications including comparative and non-comparative studies
about continuous hemodialysis or hemofiltration (N = 67, N = 3033)
between 1984 and 1994 revealed a trend to a decreasing mortality rate
(P < 0.08), whereas the mean age and Apache II scores did not change
over the years. To establish whether the quality of treatment has improved
as a function of time, two quality factors (OF) were created, that is, OF for
age (mean age/mean mortality rate of the patients treated) and OF for
severity of diseases (mean Apache lI/mean mortality rate). Both OF
improved from 1984 until 1994, when analyzed for continuous (P < 0.001)
or intermittent (P < 0.001) treatment modality. Thus, the quality of
treatment of patients with acute renal failure improved during the last
decade. However, there is no evidence with respect to survival rate that a
continuous renal replacement therapy is superior to an intermittent one.
Hypercalcemia in calcitriol-treated chronic dialysis patients: Role of
bone disease. D. Kiss, J. Haifmann, and A.J. Oiah, Nephroiogie, Mediz-
inische Kiinik, Kantonsspitai Liestal, Basel, Anatomisches Institut der Uni-
versitats Bern, Bern, Switzerland. In several studies the benefit of calcitriol
therapy in chronic dialysis patients (HD patients) could be demonstrated.
The risk of calcitriol therapy is the development of hypercalcernia (HC) in
many patients. To find out the reason of HC we investigated 30 HD
patients treated with oral calcitriol (0.25 to 1.0 jrg/3 X week) for secondary
hyperparathyroidism (i-PTH >200 pg/mI) over a period of 24 months.
Besides the monthly measurement of the biochemical bone parameters
(serum calcium, serum phosphorus, alkaline phosphatase, intact PTH,
Serum Osteocalcin) a double tetracycline labeled iliac biopsy was per-
formed. Calcitriol therapy was adapted to S concentration. During the
24 months, 19 patients (63%) became HC (SCa >2.60 mmol/liter). In all
patients the dialysate-calcium concentration was lowered (1.50 rnmol/
liter). Due to recurrent HC in 10 patients the calcitriol therapy had to be
stopped. Data are expressed as mean so.
Hypercalcemia Normocalcernia
LTBD 19/20 1/20
HTBD 0/10 10/10
Dialysis-time years 6.5 2.1 3.2 2.4
i-PTH pg/mi 132 174 299 265
Osteocalcin ng/mi 100 78 216 160
Calcium mmoi/iiter 2.66 0.19 2.30 0.21
Phosphate mmol/hter 1.98 0.81 1.66 0.37
CaCO3 g/day 4.41 2.23 4.36 2.34
Calcitriol ,ug/week 1.19 0.88 1.61 1.12
The biopsy result revealed LTBD (low turnover bone diesease) in 20
patients and HTBD (high turnover bone disease) only in 10 patients. All
hypercalcemic episodes were only in patients with LTBD. The incidence
of LTBD has impressively increased. This probably due to the increased
time on dialysis. Due to the widespread of the biochemical bone param-
eters it is often impossible to predict the type of bone disease and the risk
of HC. To prevent HC the indication for calcitriol therapy should be based
on the hone turnover status.
Decrease of urea-clearance in predilution hemodiafiltration with on-
line production of bicarbonate infusate. D. Kiss and J. Haifmann, Neph-
rologie, Medizinische Khnik, Kantonsspital Liestal, Liestal, Switzerland.
High-flux hemodiafiltration (HDF) presently offers the most efficient
extracorporal treatment modality in patients with end-stage renal disease.
On-line production of substitution fluid by cold sterilization of dialysate
permits virtually unlimited fluid volume exchange. If this is due to the
system and treatment induced changes (lowering of the dialysate flow rate
during on-line HDF and lowering the solute concentration in pre-HDF
and consequently lowering the driving gradient for diffusion) there should
be a decrease of the low molecular clearance. We performed urea-
clearance (Curea in mI/mm) studies and determined the heta-2 microglubu-
lin reduction rate (132m RR) during hemodialysis (HD), predilution-HDF
(pre-HDF) and post-dilution-HDF (post-HDF) with different quantities
of infusate in 6 chronic hemodialysis patients. We used a Gambro AK-100
ultra-pure dialysis machine for HD and on-line HDF and a high-flux
dialyzer (Polyflux 21). The treatment time was 240 minutes, the blood flow
rate was set at 400 mi/mm and the dialysate flow rate was 700 mI/mm.
Urea clearance was calculated on pre-, post-treatment and dialysate
concentration results. Data are expressed as mean (N = 12) so.
Infusate (lit) HD 0
Pre-HDF
5 20 40
Cura mI/mm
I32mRR%
235 13
61±10
220 14
59±14
215 12
64±7
203 16
61±12
Infusate (lit)
Post-HDF
2.5 10 20
Cur,,a mi/mm
/32mRR%
227 20
56±7
225 17
55±20
225 16
78±5
In pre-HDF with on-line production of infusate there is a continuous
decrease of the the Curea that seems to be dependent of the infusate. In
comparison to HD there is a significant (P < 0.05) decrease (— 14%)of the
Cur,,. In post-HDF with on-line production of infusate there is only a
slight (—4%), not volume dependent decrease of the Curea. The /32m RR
only increased in high volume post-HDF (+ 17%) and did not change
during pre-HDF. Therefore, the lowering of the solute concentration by
pre-HDF with a decrease of the driving gradient for diffusion seems to be
the main factor for this continuous decrease of the low molecular
clearance.
Reduced carbohydrate content of Tamm-Horsfall glycoprotein (THP)
from severely recurrent idiopathic renal calcium stone formers (RCSF).
B. Hess, M. Jaggi, L. Zipperie, and Ph. Jaeger, Medizinische Universitdtspo-
hklinik, Inseispital Bern, Bern, Switzerland. Some RCSF excrete THP
molecules which more pronouncedly self-aggregate than normal THPs at
low pH and high Na concentrations. This results in an increase in THP
viscosity, which goes along with reduced inhibition or even promotion of
aggregation of CaOx monohydrate (COM) crystals. Since biological
activity of THP might be governed by its carbohydrate moieties, we
analyzed carbohydrates of THP molecules from 8 male controls (C) and 8
male RCSF. Polyacrylamide gel electrophoresis of individual THPs (5 rg)
was first performed at denaturing conditions (SDS) on gradient gels
(4—15%), where all THP5 from C and RCSF exhibited a single band at 80
kDa. At non-denaturing conditions (17.5 ms histidine, 17.5 ms 2-[N-
morpholino]-ethane-sulfonic acid, pH 6.2), several bands became visible,
according to various states of self-aggregation of THP molecules. THPs
were then blotted onto nitrocellulose and incubated with various digoxi-
genin-labeled lectins. In addition, inhibition of COM crystal aggregation
by 40 mg/liter of individual THP was measured at pH 5.7/200 mM NaCI.
All values are means SE. Compared with THPs from C, THPs from
RCSF appeared to be more self-aggregated on native gels, All stone
former THPs very weakly reacted with lectins WGA (specific for 131-linked
N-acetyl-glucosamines), MAA (sialic acid terminally a2-3-linked to galac-
tose) and SNA (sialic acid terminally a2-6-linked to galactose). No
differences between THPs from RCSF and C were noted with RCA
(terminal 131-linked galactoses) and DSA (galactoses 131-linked to N-acetyl
glucosarnine). The average inhibition of crystal aggregation by THPs from
RCSF was —23.0 17.1%, that is, 5 out of 8 proteins actually promoted
aggregation, whereas all normal THPs inhibited it (64.0 9.8%, P = 0.003
vs. RCSF). In conclusion, THP molecules from severely RCSF contain less
carbohydrates (mainly sialic acid) than those of C. This structural abnor-
mality goes along with reduced inhibition or even promotion of COM
crystal aggregation in vitro.
High calcium (Ca) intake prevents hyperoxaluria during severe oral
oxalate (Ox) loading. B. Hess, C. Jost, R. Takkinen, and Ph. Jaeger,
Medizmnische Universitatspolikimnik, Inseispital Bern, Bern, Switzerland. It
has been repeatedly demonstrated that low Ca intake induces hyperox-
aluria (HO). To test whether high Ca intake lowers intestinal Ox
absorption and prevents HO durin severe Ox loading, 6 healthy men (age
24—44 years, BMI 22.0—25.9 kg/rn ) collected three 24-hr urines, once on
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free-choice diet ("Basal") and twice on a standardized diet (2545 kCal,
2500 ml mineral water, 102 g protein, 13.6 g NaCI, 2220 mg Ox), either
with 1214 mg Ca ("Ox") or with 3844 mg Ca ("Ca & Ox") from mineral
water and dairy products. Values are means SE. Results are in
mmol/day, except for AP (CaOx) index EQ, an estimate of the ion activity
product of CaOx (Tiselius, t991).
Measurement Basal Ox Ca &Ox
< V 4.8 0.7 3.4 0.5 8.0 0.9'
U0,, x V 0.35 0.06 0.70 0.14 0.28 0.05"
Ucy X V
AP (CaOx) index EQ
0.29 0.06
0.64 0.23
0.27 0.06
0.44 0.10
0.21 0.05
0.27 0.08i
"P = 0.028 vs. Ox
"P = 0.028 vs. Basal
Thus, the high amount of Ca administered together with the 20-fold intake
of oxalate on Ca & Ox was able to totally abolish the HO observed in 5 out
of 6 subjects on Ox (U0, X V 0.54 — 1.34 mmol/day). Since urinary
glycolate (Glyc) excretion rates remained unchanged throughout the
study, differences in U0 X V observed under the 3 conditions must reflect
respective variations in the intestinal absorption of Ox. In conclusion,
increasing Ca intake while eating highly Oxrich food prevents dietary HO.
This further illustrates the fact that idiopathic calcium stone formers
should not reduce their calcium intake below normal.
Adequacy of CAPD: Creatinine appearance index to assess compliance.
A. Fischer, P. Dreifnss, and PP. Brunner, Abteilung für Nephrologie,
Departement Innere Medizin, Kantonsspital Base!, Base!, Switzerland. The
adequacy of peritoneal dialysis, as assessed by urea and creatinine kinetics,
remains an area of controversy. One potential cause of discrepancy
between the amount of dialysis (Kt/V) and clinical outcome is patient
noncompliance with the dialysis prescription (fewer exchanges than
prescribed). Kt/V, weekly creatinine clearance, nPCR, and creatinine
appearance (CrAp) were determined by 24 hour dialysate and urine
collection in 37 stable CAPD patients. Mean Kt/V for the 48 observations
was 2.01 0.44 (so), and 27% of Kt/V measures were inferior to 1.7
(inadequate dialysis). Similarly, 23% failed to attain the target level of 50
liter/week/1.73 m2 creatinine clearance, nPCR reached the recommended
1.2 g!kglday only in 27% of observations [mean 1.00 0.28 (SD)]. Total
creatinine appearance (TCrAp = creatinine excretion measured in dialy-
sate and urine + extrarenal creatinine degradation) was compared with
the predicted creatinine appearance (PCrAp) according to the formulae
developed by Cockcroft and Gault, and a creatinine appearance index was
calculated (TCrAp/PCrAp). The mean value for this index was 109%
19% (SD). In 25% of all observations the index was superior to 124%,
which has previously been considered to reflect noncompliance. If several
confounding causes (overestimation of extrarenal creatinine degradation,
increased consumption of meat during collection, early peritonitis, ete)
can be excluded, noncompliance is the likely cause for this high index.
Noncompliance before the 24 hour collection leads to increased creatinine
and urea appearance and thus to overestimation of Kt/V, weekly creati-
nine clearance and nPCR. Collection of dialysate and urine during three
consecutive days may prove to be useful to confirm noncompliance in such
patients.
Removal of low molecular weight substances and (J microglobulin
(2m) during high-flux hemodialysis (HD) and hemodiafiltration (HDF):
A quantitative assessment. C. Zehnder and A. Blumberg, Kantonsspital,
Aarau, Switzerland. HDF increases the convective transport across dialysis
membranes. In this prospective study we evaluated the mass transfer
(Mtd) and clearance (Ku) of urea (u), creatinine (Cr), phosphate (P04)
and /32m during high-flux HD and HDF, which adds convection to
diffusion. Sixteen patients were studied with 1.6 and 2.4 m2 polysulphone
(PS) capillary filters during 4 one-week periods: Period I HD 1.6; Period
II HD 2.4; Period III HDF 1.6, and Period IV ITIDF 2.4 m2. Treatment
time was 4 hours, blood flow rate 300 ml/min with constant dialysate (Q1)
and ultrafiltration (Q1) rate. Mtd and K,, were measured during the
mid-week treatment by dialysate and ultrafiltrate collection. (Qd + Qf
527.9 on HD, 851.3 mI/mm on HDF). Removal of u and Cr was not
improved by HDF, which, however, increased P04 elimination and K,,
2m (see table).
1.6 m2 2.4 m2
HD HDF HD I-IDF
Mtd mmol 515.0 478.0 521.4 485.1
K,, mI/mm 186.0 180.6 205.0 205.1
Mtdcr mmol 11.5 10.3 12.3 11.1
K4( mI/mm 97.5 91.1 110.0 104.0
Mtd0, mmol 26.8 33.0" 29.2 37.4"
Kd04 mI/mm 103.8 126.9" 129.6 168.4c
Mtd,,,, mg 183.4 217.8 241.4 223.2
Kd,rn mI/mm 38.6 62.6" 62.0 757b
HD/HDF: 'P < 0.05; b P < 0.01; "P < 0.005.
Conclusions: HDF had no advantage over high-flux HD with respect to u
and Cr removal, hut improved the transport of P04 and clearance of 2m.
2m was adsorbed by PS as shown by the discrepancy of Mtd versus K,,.
Long-term low calcium dialysis and secondary hyperparathyroidism in
continuous ambulatory peritoneal dialysis (CAPD). T. Weinreich and J.
Passlick-Deetjen, for the Multicenter Study Group, Abteilung für Nephrologie,
Universitatsspital Zurich, Zurich, Switzerland; and Fresenius AG, Bad
Homburg, Germany. Low dialysate calcium concentrations have been
recommended for the prevention of frequent hypercalcemic episodes in
CAPD patients treated with calcium containing phosphate binders. How-
ever, the long-term complications of this treatment are still poorly defined.
We performed a controlled multicenter study in 64 stable CAPD patients
[age 54.8 years (20—71); 46 M, 18 F] randomly alloted to dialysis treatment
with either a standard (1.75 mM; S,,) or a low calcium dialysate concen-
tration (1.0 mM; L() for 2 years. All patients received CaC0 as oral
phosphate binders to adjust P04 < 2.0 mat In case of hypercalccmia
CaCO3 was stepwise exchanged for Al(OH)5. Patients received oral
ealcitriol (0.25 pg/day) if PTH (1-84) exceeded twice the upper limit of
normal. Data were analyzed on an intent to treat basis and are given as
mean so; aluminum, osteocalcin (OC) and PTH (1-84) as median!
range.
Lea (N = 35)
Month 0 Month 6 Month 24
tCa mM 2.5 0.28 2.31 0.28 2.4 0.25
i-Ca mM 1.24 0.2 1.19 0.24 1.21 0.25
P04 mM 1.8 0.46 2.0 0.48 1.97 0.83
Aluminum xg/liter 23 (11—90) 18 (4—77) 19 (6.4—90)
OC jig/liter 12(1—121) 17 (1.7—190) 15 (1.7—190)
PTHpM 14(1—125) 14(1.2—125) 17(1—175)
(N = 29)
Month 0 Month 6 Month 24
tCa mivi 2.44 0.23 2.52 0.22" 2.47 0.3"
i-Ca mM 1.21 0.19 1.28 0.13" 1.24 0.19"
P04 mM 1.85 0.45 2.02 0.49 1.89 t).44
Aluminum p.g/liter 19 (5—147) 22 (6—102) 34 (7—137)"
OC p.g/liter 11(1—60) 10 (1.2—36)" 9 (1—60)"
PTHpM 6.4 (1—71)" 7(1—136)" 7.5 (1—100)"
"Significantly different to LCa; mANOVA
Hypercalcemic episodes were about three times as frequent in S, as in
L( patients (P 0.03). Median AI(OH)1 intake was 1.44 (0—8.4)
tablet/day in versus 0.1 (0—7) tablet/day in L, (P = 0.011). The
cumulative daily dose of phosphate binding tablets was identical in both
groups. Eight of 35 patients on developed severe sHPT (PTH > 60
pmol) versus 3 of 29 on S,.,. Bone mineral density did not change in both
groups during the study period. In conclusion, long-term treatment with
low calcium dialysate solutions lowers the incidence of hypercalcemia in
CAPD pts but carries a certain risk to aggravate sHPT despite adequate
Ca control.
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A new algorithm for modeling glomerular ultrafiltration: Role of
glomerular resistance. H. Andreas Bock, Abteilung Nephrologie, Kantons-
spital Basel,Switzerland. Current models of glomerular filtration system-
atically disregard glomerular capillary resistance (Rgjon,), even though
blood flow within the glomerulus is driven by a longitudinal (axial)
pressure gradient. This neglect is particularly unrealistic in glomerular
disease, where glomerular capillary number and diameter are often greatly
reduced. A new PC-based iterative algorithm, which takes Rgi0n as the
input in addition to conventional parameters, was therefore developed
and used for modeling glomerular ultrafiltration in the cuvolemic rat and
the human glomerulus. In the latter, the glomerular ultrafiltration coeffi-
cient (Kf) was assumed to be between 5 and 20 nI/mm/mm 1-1g. Using the
algorithm for fitting in vivo data, an axial intraglomerular pressure drop
of 5 mm Hg was computed for normal glomeruli of both rat and human.
Unlike existing models, the new algorithm predicts that reverse filtration,
not filtration equilibrium, occurs in the glomerular capillary beyond the
point where net ultrafiltration pressure reaches zero. According to the
model, reverse filtration should normally occur in human glomeruli with a
Kf> 9, and in any case at low end-afferent pressure (Pc,1 43 mm Hg
for humans with Kf = 5, ,,,dafi 38 mm Hg for euvolemic rats).
Significant R1,,-dependent changes of SNGFR only occur at very low
blood pressures or extreme values of Rgo,,,. However, increasing Rgi,,, at
normal pressure leads to reverse filtration at a 6.4-fold increase in the rat
and at a 3.2-fold increase in human at Kf = 5. Finally, the model predicts
that, although the measured "equilibration ratio" [RI = flc4crcnt/(P0c —
PtUh) of a glomerulus may be > I in individual micropunctures, the mean
of such measurements should not exceed 1, if puncture sites are truly
random. In conclusion, this analysis suggests that the early studies on
which the concept of a negligible Rgion, rested, were biased, since most of
them reported mean values of [RI > 1. The axial intraglomerular pressure
drop under normal conditions is estimated to be approximately 5 mm Hg.
SNGFR appears to be fairly insensitive to changes of R510,,. Partial reverse
filtration, not filtration equilibrium, is predicted to occur (a) in human
glomeruli with a high Kf, (h) in rat and human glomeruli at low
end-afferent pressure, and (c) in diseases which increase Rgion, at least
three-fold.
Effects of cyclic AMP on NatK-ATPase activity and phosphorylation
in renal cortical tubules. M.L. Carranza, E. Féraille, M. Rousselot and H.
Favre, Hôpital Cantonal Universitaire, Genève, Switzerland. Na + ,K -
ATPase is a key enzyme in any cell type, playing an important role in the
regulation of cell volume and intracellular ions concentration. Its function
is more crucial in the kidney, where this enzyme drives most of tubular
reabsorption process. Thus, understanding the mechanism of its regula-
tion by hormones is of great importance. Cyclic AMP (cAMP) has been
implicated in the control of Na,K-ATPase activity in various cell types.
In proximal convoluted tubules (PCT), Na,K-ATPase activity measured
by electrophysiological methods is increased by cAMP analogues. To
further characterize the effect of cAMP on the PCT enzyme, we investi-
gated the correlation existing between phosphorylation state of Na,K-
ATPase and Rb uptake. 32P-labeling of the Na ,K -ATPase was
analyzed after immunoprecipitation of the enzyme from cortical tubules
suspension and cation transport activity of the Na,K-ATPase was
measured by ouabain-sensitive wRb influx in isolated rat PCT. Tubules
were incubated either with cAMP analogues [8-bromo-cAMP, dibutyryl-
cAMP (db-cAMP)I or forskolin plus 3-isobutyl-1-methylxanthine. After 15
minutes of incubation at 37°C in the presence of one of these compounds,
phosphorylation and 8'Rb uptake were increased. Increasing concentra-
tions of db-cAMP (i0- M to 10 M) resulted in a dose-dependent
increase in both phosphorylation and 86Rb uptake. Incubation with
inhibitors of the PKA (H-89 or Rp-eAMPS, a cAMP analogue that inhibits
protein kinase A), blocked the effects of db-cAMP, suggesting that this
compound acts through activation of the PKA. These results show that, in
the rat PCT, activation of PKA increases the Na,KtATPasemediated
cation transport through phosphorylation of the enzyme. Therefore,
hormones acting through the activation of adenylate cyclase, which leads
to a raise in intracellular cAMP content, may control tubular Na,K-
ATPase activity by this way.
Insulin stimulates Na-K-ATPase activity and increases tyrosine phos-
phorylation of its a-subunit in rat cortical tubules. E. Féraille, ML.
Carranza, M. Rousselot, J. Caverzasio and H. Favre, Hôpital Cantonal
Universitaire, Genève, Switzerland. In the rat proximal convoluted tubule,
insulin increases the Na reabsorption at least in part through a direct
stimulation of the Na-K-ATPase activity. Tyrosine phosphorylation is the
key process of the insulin-signaling pathway. We therefore investigated the
capacity of tyrosine phosphorylation to modulate the Na-K-ATPase.
Using a suspension of rat cortical tubules, we determined the effects of
insulin on: (1) the Na-K-ATPase activity measured by the ouabain-
sensitive 86Rb uptake, (2) the tyrosine-phosphorylation level of the
Na-K-ATPase estimated from tyrosine phosphoproteins immunoprecipi-
tates as the amount of a-subunit detected by immunoblot. Thirty mm at
37°C incubation with 10 M insulin increased ouabain-sensitive wRb
uptake and tyrosine phosphorylation of the Na-K-ATPase a-subunit 1.5-
and 2-folds, respectively. Time courses (detected after 15 mm) and dose
dependencies (threshold at l0' M and maximal effect at 10 M) of the
insulin induced increase in Na-K-ATPase activity and tyrosine phosphor-
ylation level were parallel. These effects of insulin on both ouabain-
sensitive 86Rb uptake and tyrosine phosphorylation of Na-K-ATPase were
abolished by i0- M genistein, a specific tyrosine kinase inhibitor. In
conclusion, in rat cortical tubules, the short-term control of Na-K-ATPase
activity by insulin is dependent at least in part on tyrosine phosphorylation
of the Na-K-ATPase a-subunit through a genistein-sensitive process.
These findings open the way for new physiological mechanisms of the
control of tubular sodium reabsorption.
Urinary phosphate, magnesium and calcium to creatinine ratios in a
normal pediatric population. V. Matos, G. van Melle, 0. Boulat, D. Bardy
and i-P. Guignard, Service de Pediatric, CHUV, Institut Universitaire de
Médecine Sociale et Preventive and Laboratoire Central de Chimie Clinique,
CHUV Lausanne, Switzerland. Up to now there were no reference values
for the urinary excretion of phosphate (P04) in infants and children. The
aim of the present study was to determine P04 to creatinine (Cr) ratios
and, simultaneously, to establish the reference values for calcium (Ca) and
magnesium (Mg) to Cr ratios in infants and children. The second morning
urine was collected from 382 infants and children (188 females and 194
males, aged 1 month to 17 years, median 4.5 years, from Lausanne
kindergartens and schools), whose parents had given written consent. In
74% of the children, a second urine sample was obtained a week later, thus
allowing the analysis of intra-individual variations as well. P04, Mg and Ca
concentrations were measured using reactions with molybdate, xylidil blue
and o-cresol-phtalein, respectively, Cr concentration was measured with a
Jaffe's kinetic method. All the tests were performed on a Hitachi 704
(Bochringer, Switzerland). The 95th (P95) and 5th centiles were estimated
for the three mineral-to-creatinine ratios from 664 urine samples. A
nonlinear regression in terms of age and sex was used to smooth the
nonparametric estimates of these centiles. There was no significant
difference between sexes. For illustration, the 95th centile, derived from
the mathematical model, is presented here for five classes of age:
P95
(mol/mol)
Age
1—3 months
6—12
months
3—5
years
7—10
years
>14
years
PO4JCr 19.5 14 8 3.6 2.7
Ca/Cr 2.6 1.5 1 0.7 0.7
Mg/Cr 2.3 1.7 1.3 0.87 0.6
Data on P04/Cr can be used as reference values for the pediatric
population. The overall results on Ca/Cr and Mg/Cr confirm values
reported previously for children older than 4 years, and provide reference
values for younger children. A steady decrease in the mineral-to-creati-
nine ratios related to age was observed. Furthermore, intra- and interin-
dividual variations also decreased significantly with age. Thus age has to be
taken into account while interpreting urinary P04, Ca and Mg to
creatinine ratios.
Why do newborn infants have elevated plasma creatinine levels? f-P.
Guignard, V. Matos, P. Hohlfeld, Départements de Pediatric et d'Obstétrique,
CHUV Lausanne, Switzerland. Elevated plasma creatinine concentrations
in neonates are usually considered to reflect maternal levels. According to
this concept, the progressive decline in plasma creatinine observed during
the first days or weeks of life is related to the elimination of an excess
creatinine transferred from the mother. We questionned this concept on
the basis of the 3 following studies. (1) Newborn infants. On the 12 to 36th
hour of life, the plasma ereatinine concentration amounted to 66 3
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smol/liter in term infants (N = 20) and 91 4 j.Lmol/liter in preterm
neonates (N = 40). The plasma creatinine was highest in the most
premature infants (28 to 30 weeks GA) who also presented with the
slowest decline in plasma creatinine during the first postnatal weeks. (2)
Pregnancies. To see whether the fetus' plasma creatinine equilibrates fully
with the mother's creatinine, and whether the mother's plasma creatinine
is the highest around the 28 to 30th week of gestation, the maternal and
fetal plasma creatinine concentrations were measured during 522 preg-
nancies followed from the 15th to the 40th week of gestation. The mean
fetal/maternal creatinine ratio never significantly differed from 1, the
mean creatinine concentration remaining below stable throughout preg-
nancy. The first conclusion, is that these two human studies indicate that
the elevated plasma creatinine concentrations present in neonates do not
reflect the maternal plasma creatinine. (3) Newborn rabbits. The clear-
ance of creatinine was measured in 20 newborn rabbits and compared to
that of inulin. In contrast with the situation in adult animals, the clearance
of creatinine significantly underestimated the clearance of inulin, with a
mean fractional reabsorption rate of creatinine of 12.6 3.7%. The
significant net reabsorption of creatinine by the immature kidney was only
present during the first weeks of life. In general, (1) elevated creatinine
plasma levels in neonates are the consequence of the net tubular
reabsorption of creatinine and are not maternal in origin; (2) during
intra-uterine life, the plasma fetal creatinine concentration is maintained
at a low level thanks to transplacental diffusion from fetus to mother. We
speculate that the presence of poreus immature tubules in neonates is
responsible for the passive back-diffusion of filtered creatinine from the
tubular lumen to the blood.
Failure of loop diuretics to prevent the hypoxemia-induced renal
vasoconstriction in the newborn rabbit. L. Dubourg, D. Mosig, J.-P.
Guignard, Departement de Pédiatrie, CHUV Lausanne, Switzerland. Hypox-
ernie conditions frequently encountered in newborn infants can, in these
conditions, lead to a state of renal insufficiency. Loop diurectics have been
claimed to improve renal function, but their beneficial effects are still not
clearly established. Torasemide, a novel mop diuretic with potassium
sparing properties, could be of interest in high risk neonates. The newborn
rabbit was used as an experimental model for studying the renal effect of
torasemide during normoxemic (Pa02  120 mm Hg) and hypoxemic
(PaO 40 mm Hg) conditions. In normoxemia, a low dose (0.2 mg/kg) or
larger dose (1 mg/kg) of torasemide induced significant, dose-related,
increase in urine flow rate (300 150% and 800 80%, respectively) and
in sodium excretion (2900 1200% and 12000 2500%, respectively). A
fall in renal plasma flow (RPF) was observed with the larger dose (28.7
9.3%,P < 0.05),without changes in glomerular filtration rate (GFR). The
fall in RPF was prevented by continuously compensating the water and
sodium losses. The increase in renin secretion and angiotensin production
which occurs during diuretic therapy probably explain these results.
Torasemide (1 mg/kg) remained effective in hypoxemic conditions: urine
flow rate and sodium excretion increased by 220 35% and 5550
1600%, respectively. However, torasemide failed to prevent or blund the
deleterious effect of hypoxemia on renal hemodynamics, in control or
torasemide treated newborn rabbits, hypoxemia was indeed associated
with a similar fall in GFR (24.2 2.9% and 26.4 5.4%, respectively) and
RPF (26.2 4.1% and 32.8 43.5%, respectively). We conclude that
while the administration of loop diuretics can increase urine flow and
sodium excretion rates in the hypoxemia-induced vasomotor nephropathy,
it apparently fails to improve GFR and RBF. The same conclusion
probably applies to oliguric human neonates.
The Swiss Living Kidney Donor Registry since 1993. G. Thiel, Jbr
Swisstransplant and the Swiss Society of f\Iephrology, Kantonsspital Basel,
Basel, Switzerland. Since April 1993 all kidney transplants with a kidney
source from living donors have been registered in a newly founded Swiss
Living Kidney Donor Registry. Several goals were hoped to be achieved by
this Registry: (1) clarity about the living kidney donor source; (2)
prospective evaluation of renal function (plasma creatinine, urinary
protein, urinary-albumin), blood pressure, antihypertensive treatment; (3)
prospective evaluation of the well being of the donors or complaints and
complications; and (4) accumulation of objective data for future advice of
potential living kidney donors. All donors have to fill out a form just
before donation to answer questions about their relation to the recipient,
their well being, complaints, drug consumption, etc. Blood pressure is
recorded and a urinary sediment is examined. A blood sample for plasma
creatinine, and a morning spot urine sample (albumin, protein, creatinin:
alb/cr and Prot/cr ratios) were sent to a common central laboratory (Dr.
Viollier, Basel). At 1,3,5, 10, 15,20 years, etc., after donation, the donors
are requested to fill Out a similar questionnaire, and their general
physician is asked to complete the form by measuring blood pressure,
examining the urine and to sending a blood sample and a morning spot
urine sample to the central laboratory, The data were recorded in the
Registry and have been presented annually at a meeting of Swisstransplant
and at the annual congress of the Swiss Society of Nephrology. Since April
1993, 88 living kidney donors were registered, and 44 of them have been
followed for one year after donation. Sixty-three were related to the
recipient (23 mothers, 9 fathers, 19 sisters, 12 brothers) and 21 unrelated
(13 wives, 5 husbands, 2 unmarried concubine life's companion, one
father-in-law). Fourteen donors came from abroad, the sex ratio was 56
female and 28 male donors, and donor ages ranged from 25 to 72 years
(mean 49 years). At one year after donation, p creatinine increased from
a mean of 85 to 113 jtmol/liter, urine protein/cr has dropped from 12.5 to
8.5 (normal upper range = 15 mg protein/mmol Ut,), as well as albumin/cr
from 2.5 to 1.1 (normal upper range 3mg alb/mmol Cr). Four of 44 donors
reported taking an additional drug since donation. In conclusion, a
National Donor Registry is the only way to achieve clarity about the living
donor source and the true complication rate of living donation. The
Registry can also pick up donors in time who develop hypertension and
are not yet appropriately treated. To our knowledge, this is the first
National Living Kidney Donor Registry in the world.
